Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?
2026-07-14 21:07
•Brendan Coffey •The Motley Fool
•• • Axe Capital view
Glaukos CFO Stock Sale Isn’t a Red Flag—Here’s Why
A $1.6 million insider sale at Glaukos is by the book and doesn't signal trouble.
When an insider unloads shares, alarm bells often ring. But not all sales are equal. Glaukos’ CFO sold shares under a Rule 10b5-1 plan set months ago, which lets insiders sell on autopilot, avoiding accusations of trading on inside info. The company’s growth story remains intact, with projected revenues climbing 25% to $630 million in 2026 and an innovative glaucoma drug, Epioxa, that could pull in over $1 billion by 2030. For South African investors, this points to a positive risk appetite for emerging health tech, even as local markets like the JSE focus more on financials and miners. The rand (USD/ZAR) may not react much since this is purely a US healthcare story. Still, watch this space for a potential thematic play; for now, patience pays. If demand for US tech cools or regulatory hurdles pop up, this optimism could falter. this is just my opinion and not financial advice
Wait on Glaukos for now—there’s no urgency to buy given the insiders are offloading systematically. Instead, keep an eye on USD/ZAR for shifts in risk sentiment that could affect your overall portfolio.
- GKOS
- USD/ZAR
- Regulatory delays on Epioxa approval
- Global tech sell-off affecting healthcare specialty stocks
5/10
Glaukos CFO Alex Thurman sold 10,000 shares worth $1.6 million on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in December 2025. While insider sales can raise concerns, the non-discretionary nature of this transaction and Glaukos' strong growth outlook—including 25% projected revenue growth for 2026 and the promising Epioxa product—suggest the sale does not indicate trouble for the company.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Brendan Coffey
Categories: Equities, Earnings
Tickers: GKOS
Sentiment: Positive - Despite the CFO's stock sale, the company maintains a bullish outlook with projected 25% revenue growth to $630 million in fiscal 2026, expected swing to profitability in 2027, and significant upside potential from the Epioxa product which could generate over $1 billion in revenue by 2030. The non-discretionary nature of the sale under a pre-established trading plan mitigates bearish concerns.
Keywords: insider trading, stock sale, Rule 10b5-1 trading plan, ophthalmic medical devices, glaucoma treatment, revenue growth, Epioxa product
Insights:
- GKOS: Positive: Despite the CFO's stock sale, the company maintains a bullish outlook with projected 25% revenue growth to $630 million in fiscal 2026, expected swing to profitability in 2027, and significant upside potential from the Epioxa product which could generate over $1 billion in revenue by 2030. The non-discretionary nature of the sale under a pre-established trading plan mitigates bearish concerns.